These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18477049)

  • 1. A case of fatal pulmonary embolism raising questions about the dosing regimen for dalteparin in the very obese.
    Walden A; Levison R; Singh S; Keeling D
    Br J Haematol; 2008 Jul; 142(3):487-9. PubMed ID: 18477049
    [No Abstract]   [Full Text] [Related]  

  • 2. [Thrombolysis in pulmonary embolism with unstable hemodynamics can be life-saving. Discussed treatment strategy--two cases illustrate the problem].
    Söderberg M; Edsberg J
    Lakartidningen; 2008 Oct 29-Nov 4; 105(44):3112-4. PubMed ID: 19031977
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of pulmonary embolism in an extremely obese patient.
    Diepstraten J; van Kralingen S; Snijder RJ; Hackeng CM; van Ramshorst B; Knibbe CA
    Obes Surg; 2009 Aug; 19(8):1186-9. PubMed ID: 19506978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burns in morbidly obese patients.
    Sheridan RL; Rue LW; McManus WF; Pruitt BA
    J Trauma; 1992 Dec; 33(6):818-20. PubMed ID: 1474621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on 238 fatal lung embolisms in the Freiburg Surgical University Hospital (1952-1963)].
    Lorenz D; Ruppin H
    Med Welt; 1967 Jun; 23():1441-5. PubMed ID: 5617426
    [No Abstract]   [Full Text] [Related]  

  • 7. Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
    Moore A; Lau E; Yang C; Mackool B; Kuter DJ
    Am J Clin Oncol; 2007 Jun; 30(3):329-31. PubMed ID: 17551316
    [No Abstract]   [Full Text] [Related]  

  • 8. Heparin dosing in the morbidly obese patient.
    Holliday DM; Watling SM; Yanos J
    Ann Pharmacother; 1994 Sep; 28(9):1110-1. PubMed ID: 7803893
    [No Abstract]   [Full Text] [Related]  

  • 9. Weight-based administration of dalteparin in obese patients.
    Smith J; Canton EM
    Am J Health Syst Pharm; 2003 Apr; 60(7):683-7. PubMed ID: 12701550
    [No Abstract]   [Full Text] [Related]  

  • 10. Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.
    Ganguli A; Walker L; FitzGerald RJ; Pirmohamed M
    Ann Pharmacother; 2009 Sep; 43(9):1528-31. PubMed ID: 19690222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abdomen pendulum and subcutaneous injections: the complications. Two case reports].
    Benhaim T; Sinna R; Garson S; Boloorchi A; Crozet C; Robbe M
    Ann Chir Plast Esthet; 2007 Jun; 52(3):211-7. PubMed ID: 17316950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are we ready to start outpatient treatment for pulmonary embolism?
    Meyer G
    Thromb Haemost; 2008 Nov; 100(5):736-7. PubMed ID: 18989512
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cerebral hemorrhage in spite of proper anticoagulant therapy (fatal drug interaction)].
    Schneider V
    Beitr Gerichtl Med; 1982; 40():413-22. PubMed ID: 6086135
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.
    Ugaki H; Enomoto T; Fujiwara K; Kimura T; Kawasaki T
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):585-9. PubMed ID: 18685443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prejudice.
    Cheng GS
    Hastings Cent Rep; 2006; 36(5):8-9. PubMed ID: 17091690
    [No Abstract]   [Full Text] [Related]  

  • 17. Pitfalls in patient self-management of subcutaneous drug application: removal of rubber protection caps from ready-to-use syringes.
    Mengiardi S; Goepfert B; Tsakiris DA; Hersberger KE
    Eur J Clin Pharmacol; 2009 Oct; 65(10):1061-2. PubMed ID: 19536529
    [No Abstract]   [Full Text] [Related]  

  • 18. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 8(th) American College of Chest Physicians Guidelines - a perspective on venous thromboembolism guidelines.
    Squizzato A; Ageno W
    Thromb Haemost; 2009 Jan; 101(1):31-5. PubMed ID: 19132186
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.